ctDNA-Guided Neoadjuvant Therapy in HER2+ Breast Cancer
Individualized Neoadjuvant De-Escalation of T-DXd in HER2+ Breast Cancer (INDEX-HER2)
The convergence of evidence from neoCARHP (comparable pCR between TCHP and THP in an unselected population), DB-11 (activity of T-DXd-THP in high-risk HER2-positive early breast cancer), and I-SPY2 ctDNA data (early ctDNA clearance predicts favorable response and outcomes) provides a strong rationale for biomarker-guided treatment selection. This study uses early on-treatment ctDNA response after standardized THP induction to direct therapy intensity rather than reflexively escalating all patients.
Unlike non-biomarker-selected escalation approaches, this study uses ctDNA as a dynamic biomarker to tailor therapy: patients with early molecular clearance continue THP without carboplatin or ADC exposure, while patients with persistent molecular tumor burden escalate to T-DXd.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Clinical Trials Navigator
- Telefonnummer: 310-423-2133
- E-Mail: groupcancertrialinformation@cshs.org
Studienorte
-
-
California
-
Beverly Hills, California, Vereinigte Staaten, 90212
- Cedars-Sinai Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Newly diagnosed, histologically confirmed stage II-III HER2-positive breast cancer (HER2-positive defined per ASCO/CAP guidelines: IHC 3+ or ISH-amplified)
-
No prior systemic therapy for breast cancer
-
Adequate tumor tissue available for molecular profiling and ctDNA assay design
-
Adequate peripheral blood samples obtainable for serial ctDNA testing
-
Age ≥ 18 years
-
ECOG performance status 0-2
-
Adequate organ function as defined by:
- Absolute neutrophil count (ANC) ≥ 1,500/µL
- Platelets ≥ 100,000/µL
- Hemoglobin ≥ 9.0 g/dL
- Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
- AST/ALT ≤ 2.5 × ULN
- Creatinine clearance ≥ 50 mL/min (Cockcroft-Gault)
- Left ventricular ejection fraction (LVEF) ≥ 55% by echocardiogram or MUGA scan
-
Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during treatment and for the protocol-specified period after the last dose of HER2-directed therapy/T-DXd, per applicable prescribing information and institutional standards.
-
Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
Exclusion Criteria:
- Distant metastatic disease (Stage IV)
- Prior invasive breast cancer within the past 5 years
- Prior chemotherapy, radiation therapy, or targeted therapy for current breast cancer
- Known hypersensitivity to any component of the treatment regimen, including docetaxel, trastuzumab, pertuzumab, or T-DXd
- Active cardiac disease including: congestive heart failure (NYHA Class II or above), unstable angina, myocardial infarction within 6 months, uncontrolled hypertension, or clinically significant arrhythmia
- Pregnant or breastfeeding
- History of, or current, interstitial lung disease/pneumonitis; active uncontrolled infection requiring systemic therapy
- Any other condition that, in the opinion of the investigator, would make the patient unsuitable for study participation.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Einarmig
|
All patients begin with THP for Cycles 1-4. ctDNA is assessed at baseline,C2D1, C5D1, and at the preoperative and postoperative time points. C2D1 ctDNA determines subsequent treatment: ctDNA-negative patients continue THP through C6, while ctDNA-positive patients escalate to T-DXd from C5 through C8 after 4 cycles of THP. A tumor-informed, personalized ctDNA assay will be used. Whole genome sequencing (WGS) will be performed on formalin-fixed paraffin-embedded (FFPE) tumor tissue and matched-normal DNA from buffy coat to identify somatic variants. Based on the WGS results, multiplex PCR primers will be designed for 64 tumor-specific, somatic single-nucleotide variants for each patient. A sample will be considered ctDNA-positive if ≥2 of 64 variants are detected in the circulating cell-free DNA. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
pCR rate in the HR-positive/HER2-positive group
Zeitfenster: Time of Surgery, up to 24 weeks post on study
|
Pathologic complete response (pCR) is defined as the absence of residual invasive cancer in the breast and regional lymph nodes (ypT0/is ypN0) at the time of surgery following completion of neoadjuvant therapy. |
Time of Surgery, up to 24 weeks post on study
|
|
pCR rate in the HR-negative/HER2-positive group
Zeitfenster: Time of Surgery, up to 24 weeks post on study
|
Pathologic complete response (pCR) is defined as the absence of residual invasive cancer in the breast and regional lymph nodes (ypT0/is ypN0) at the time of surgery following completion of neoadjuvant therapy. |
Time of Surgery, up to 24 weeks post on study
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
ctDNA Clearance Rate
Zeitfenster: From enrollment to end of treatment at 8 cycles (24 weeks)
|
Patients who achieve ctDNA clearance during and after neoadjuvant therapy |
From enrollment to end of treatment at 8 cycles (24 weeks)
|
|
Event-Free Survival (EFS)
Zeitfenster: From time of enrollment until date of documented progression or date of death from any cause, whichever came first, assessed up to 67 months
|
Time from Enrollment to disease progression precluding surgery, local or distant recurrence, or death from any cause |
From time of enrollment until date of documented progression or date of death from any cause, whichever came first, assessed up to 67 months
|
|
Residual Cancer Burden (RCB)
Zeitfenster: Time of Surgery, up to 24 weeks post on study
|
Proportion of patients achieving RCB-0 or RCB-1 (minimal residual disease) at surgery based on molecular subtypes |
Time of Surgery, up to 24 weeks post on study
|
|
Adverse Events
Zeitfenster: From enrollment till Time of Surgery, up to 24 weeks post enrollment
|
From enrollment till Time of Surgery, up to 24 weeks post enrollment
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- IIT2026-13-Bitar-INDEX-HER2
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .